Gosset Ownership
Private
Employees
~75
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Guangzhou FineImmune Biotechnology General Information
FineImmune has developed the first personalized neoantigen-specific TCR-T cell therapy currently in Phase I clinical trial. Multiple other immune cell therapies are also in early-stage clinical development. The company claims to have solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies enabling precision prediction of efficacy and side effects of immunotherapies. Over twenty immune cell therapy products and technologies are under R&D.[5][6]
Contact Information
Primary Industry
Biotech
Corporate Office
Guangzhou, Guangdong Sheng / Guangdong Province
China
China
Drug Pipeline
Phase 1
Key Partnerships
Biocytogen Pharmaceuticals — strategic collaboration to co-develop antibody-based/cell therapies targeting intracellular tumor-associated antigens using Biocytogen’s proprietary platforms combined with FineImmune’s technology.[5][6][9][10]
Guangzhou FineImmune Biotechnology Funding
No funding data available
To view Guangzhou FineImmune Biotechnology's complete valuation and funding history, request access »